Nov 30, 2021

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel. Read the article here. 

 This contains certain forward-looking statements.